Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Applying New European Guideline Updates in AML: Experts Review Current Best Practice in Treatment and Molecular Testing—Italy

Learn more about the latest guideline updates on AML and how those changes are poised to impact practice in this webcast from the first of 2 expert roundtables.
Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD
Adolfo de la Fuente Burguera, MD
Courtney DiNardo, MD, MSCE
person default
Giovanni Martinelli, MD
Released: November 30, 2022

Information on this Educational Activity

Program Director

Claudio Cerchione, MD, PhD

Romagnolo Institute for the Study of Tumors "Dino Amadori"
Hematology Unit
Medical Director/Researcher
Hematology Unit
Istituto Romagnolo per Lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Italy

Claudio Cerchione, MD, PhD: consultant/advisor/speaker: Glycomimetics, Menarini/Stemline.

Faculty

Naval G. Daver, MD

Director
Leukemia Research Alliance Program
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval G. Daver, MD: researcher: AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Servier, Trillium, Trovagene; consultant/advisor/speaker: AbbVie, Agios, Astellas, Amgen, Arog, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, Jazz, Novartis, Pfizer, Servier, Shattuck Labs, Syndax, Trillium; independent contractor: ImmunoGen.
Adolfo de la Fuente Burguera, MD

Head of Hematology Department
MD Anderson CC Madrid
Madrid, Spain

Adolfo de la Fuente Burguera, MD: speaker: AbbVie, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Incyte, Janssen-Cilag, Jazz, Novartis, Pfizer, Roche; advisor: AbbVie, Astellas, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Incyte, Jazz, Mundipharma, Pfizer, Roche; researcher: BTG, Janssen-Cilag, Novartis.
Courtney DiNardo, MD, MSCE

Associate Professor
Division of Cancer Medicine
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, Bristol-Myers Squibb, Genmab, GlaxoSmithKline, Jazz, Novartis, Servier.
Giovanni Martinelli, MD

Associate Professor
Institute of Hematology "L. and A. Seràgnoli"
Alma Mater Studiorum
University of Bologna
Bologna, Italy
Scientific Director
Department of Hematology
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST S.r.l.
Meldola, Italy

Giovanni Martinelli, MD, has no relevant financial relationships to disclose.

Program Medium

This program has been made available online.

Related Content

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

On-demand webcast from an ASH 2022 satellite symposium on asparaginase for the treatment of AYA and adult acute lymphoblastic leukemia, from Clinical Care Options (CCO)

Daniel J. DeAngelo, MD, PhD
Program Director
Emily Curran, MD Kjeld Schmiegelow, MD, DMSci
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

Experts address audience questions from a live symposium on AML treatment strategies and future therapy directions, from Clinical Care Options (CCO)

Daniel Pollyea, MD, MS
Program Director
Courtney DiNardo, MD, MSCE Eytan M. Stein, MD
Released: January 24, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Servier Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings